Clinical and pathological characteristics of MCL with splenic involvement
| . | SOX11-negative MCL . | SOX11-positive MCL . |
|---|---|---|
| Patients | ||
| No. | 9 | 8 |
| Median age, y (range) | 70 (62-75) | 65 (42-89) |
| Sex | ||
| Male (%) | 6 (67) | 6 (75) |
| Female (%) | 3 (33) | 2 (25) |
| Histology | ||
| Small cell (%) | 4/9 (44) | 1/8 (13) |
| Classic (%) | 5/9 (56) | 7/8 (87) |
| Ki67 index, mean ± SD | 12.1 ± 9.83 | 28.63 ± 16.21 |
| Ann Arbor stage | ||
| I/II (%) | 0/5 (0) | 0/5 (0) |
| III/IV (%) | 5/5 (100) | 5/5 (100) |
| LDH level > normal (%) | 2/5 (40) | 0/2 (0) |
| Nodal involvement (%) | 2/9 (22) | 3/8 (38) |
| Leukemic involvement (%) | 7/7 (100) | 4/4 (100) |
| BM involvement (%) | 5/5 (100) | 5/5 (100) |
| Therapy | ||
| Chemotherapy (%) | 2/8 (25) | 5/6 (83) |
| Only splenectomy (%) | 6/8 (75) | 1/6 (17) |
| Mean survival, mo (range) | 96 (76-116) | 49 (31-67) |
| . | SOX11-negative MCL . | SOX11-positive MCL . |
|---|---|---|
| Patients | ||
| No. | 9 | 8 |
| Median age, y (range) | 70 (62-75) | 65 (42-89) |
| Sex | ||
| Male (%) | 6 (67) | 6 (75) |
| Female (%) | 3 (33) | 2 (25) |
| Histology | ||
| Small cell (%) | 4/9 (44) | 1/8 (13) |
| Classic (%) | 5/9 (56) | 7/8 (87) |
| Ki67 index, mean ± SD | 12.1 ± 9.83 | 28.63 ± 16.21 |
| Ann Arbor stage | ||
| I/II (%) | 0/5 (0) | 0/5 (0) |
| III/IV (%) | 5/5 (100) | 5/5 (100) |
| LDH level > normal (%) | 2/5 (40) | 0/2 (0) |
| Nodal involvement (%) | 2/9 (22) | 3/8 (38) |
| Leukemic involvement (%) | 7/7 (100) | 4/4 (100) |
| BM involvement (%) | 5/5 (100) | 5/5 (100) |
| Therapy | ||
| Chemotherapy (%) | 2/8 (25) | 5/6 (83) |
| Only splenectomy (%) | 6/8 (75) | 1/6 (17) |
| Mean survival, mo (range) | 96 (76-116) | 49 (31-67) |
BM, bone marrow; LDH, L-lactate dehydrogenase.